Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lemonade Inc (LMND) vs Smith & Nephew plc (SNN) Price & Performance

Lemonade IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Lemonade Inc vs Smith & Nephew plc — how do they compare? Lemonade Inc trades at $51.54 (market cap $4.09B), while Smith & Nephew plc trades at $29.82 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 3.1× Lemonade Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.

LMNDSNN
Market Cap
$4.09B$12.54B
Sector
FinancialsHealth
52-Week High
$96.57$38.70
52-Week Low
$47.38$28.73
Enterprise Value
$3.95B$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lemonade Inc

Lemonade (LMND) trades at $51.21, down 2.79% in the past 24 hours, with a bearish technical signal indicated by moving averages and ADX. The company reported Q2 2026 earnings that beat expectations, with revenue growth of 79% year-over-year, but remains unprofitable with a net income margin of -14.19%. Recent news highlights a CFO transition and expansion into new states, while the stock faces volatility amid mixed analyst sentiment.

The outlook for LMND hinges on achieving profitability, guided for Q4 2026, but high valuation (P/S of 4.1) and persistent losses pose risks. Opportunities include AI-driven growth and market expansion, yet investors face execution risks and competitive pressures in the insurance sector.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.

While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.

Returns comparison

Trailing returns across standard periods

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN